Jessicca Rege News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jessicca rege. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jessicca Rege Today - Breaking & Trending Today
Re-engineering proteins to develop novel immunotherapies europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
(0) DUBLIN, April 7, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ( nemvaleukin , formerly referred to as ALKS 4230), Alkermes novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD s KEYTRUDA (pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer. Under the terms of the agreement, Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021. We are pleased to collaborate with MSD to evaluate nemvaleukin in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer, a patient population for which there are limited treatment options available and overall survival remains low. I ....
Alkermes In Clinical Trial Collaboration With Merck WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) has entered into a clinical trial collaboration and supply agreement with Merck & Co. for a planned phase III study of Alkermes nemvaleukin alfa in combination with Merck s Keytruda in patients with platinum-resistant ovarian cancer, Alkermes said in a release. As per the agreement, Alkermes plans to initiate the phase III study in the second half of 2021. We are pleased to collaborate with MSD to evaluate nemvaleukin in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer, a patient population for which there are limited treatment options available and overall survival remains low. Importantly, there are no anti-PD-1 treatments currently approved for this tumor type, said Jessicca Rege, Ph.D., Vice President, Head of Oncology at Alkermes. ....
Share this article Share this article DUBLIN, April 7, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ( nemvaleukin , formerly referred to as ALKS 4230), Alkermes novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD s KEYTRUDA ® (pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer. Under the terms of the agreement, Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021. ....
Alkermes : Investor Day to Focus on Scientific Progress and Value Creation Strategy marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.